PTC Therapeutics (NASDAQ:PTCT) Stock Rating Upgraded by Wall Street Zen

03 Aug 2026, 06:18 by Mitch Edgeman · The Markets Daily

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Saturday.

Several other equities research analysts also recently issued reports on the company. Weiss Ratings downgraded PTC Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wells Fargo & Company lifted their price objective on PTC Therapeutics from $93.00 to $106.00 and gave the company an “overweight” rating in a report on Friday. Raymond James Financial assumed coverage on PTC Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $108.00 price objective for the company. TD Cowen raised PTC Therapeutics from a “hold” rating to a “buy” rating and increased their target price for the stock from $75.00 to $90.00 in a research note on Friday, May 8th. Finally, Jefferies Financial Group upgraded shares of PTC Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the stock from $76.00 to $85.00 in a report on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, PTC Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $95.75.

Check Out Our Latest Analysis on PTC Therapeutics

PTC Therapeutics Stock Performance

PTCT opened at $68.01 on Friday. The firm’s fifty day moving average is $77.57 and its two-hundred day moving average is $72.71. The firm has a market cap of $5.64 billion, a PE ratio of -117.26, a price-to-earnings-growth ratio of 5.92 and a beta of 0.56. PTC Therapeutics has a twelve month low of $43.17 and a twelve month high of $90.87.

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.68. The company had revenue of $360.52 million during the quarter, compared to analyst estimates of $298.63 million. PTC Therapeutics had a negative net margin of 3.80% and a negative return on equity of 362.45%. The firm’s revenue was up 101.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.83) EPS. Equities analysts forecast that PTC Therapeutics will post 0.41 EPS for the current fiscal year.

Insider Buying and Selling at PTC Therapeutics

In other news, VP Mark Elliott Boulding sold 5,079 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $85.08, for a total value of $432,121.32. Following the sale, the vice president directly owned 105,272 shares in the company, valued at $8,956,541.76. The trade was a 4.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mary L. Smith sold 15,834 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $90.00, for a total value of $1,425,060.00. Following the transaction, the director owned 21,813 shares of the company’s stock, valued at approximately $1,963,170. The trade was a 42.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 198,662 shares of company stock valued at $16,347,994 in the last 90 days. 5.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On PTC Therapeutics

Several hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC lifted its position in shares of PTC Therapeutics by 16.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,045 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 151 shares in the last quarter. PNC Financial Services Group Inc. grew its position in PTC Therapeutics by 8.5% in the first quarter. PNC Financial Services Group Inc. now owns 3,128 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 244 shares in the last quarter. Allworth Financial LP grew its position in PTC Therapeutics by 63.8% in the fourth quarter. Allworth Financial LP now owns 634 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 247 shares in the last quarter. Measured Wealth Private Client Group LLC increased its stake in PTC Therapeutics by 5.6% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 4,963 shares of the biopharmaceutical company’s stock valued at $377,000 after buying an additional 265 shares during the last quarter. Finally, Evolve Private Wealth LLC increased its stake in PTC Therapeutics by 5.2% in the 1st quarter. Evolve Private Wealth LLC now owns 6,122 shares of the biopharmaceutical company’s stock valued at $417,000 after buying an additional 305 shares during the last quarter.

More PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: PTC Therapeutics reported second-quarter revenue of approximately $361 million, including $239 million in product revenue, up 101.5% year over year. Adjusted earnings of $0.92 per share exceeded consensus expectations, while the company moved from a year-ago loss to a profit. PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Positive Sentiment: Sephience (sepiapterin) generated $151 million in second-quarter revenue, with management citing continued broad adoption and international expansion. This performance supports the drug’s role as a key commercial growth driver. Corporate Update and Financial Results
Positive Sentiment: The company raised its full-year 2026 outlook, projecting total revenue of $1.18 billion to $1.28 billion and product revenue of $850 million to $950 million. PTC also reported a substantial cash balance of $2.2 billion at June 30, providing financial flexibility. Corporate Update and Financial Results
Neutral Sentiment: The earnings call and follow-up analysis frame PTC Therapeutics as entering a strategically important phase, with investors focused on Sephience’s continued launch trajectory, additional pipeline opportunities and execution against the updated financial targets. PTC Therapeutics Q2 2026 Earnings Call Transcript
Negative Sentiment: Despite the headline beat and raised guidance, the stock’s reaction suggests investors may have been expecting even stronger results or a more aggressive outlook. PTC remains unprofitable on a reported basis, with a negative net margin, leaving valuation sensitive to sustained commercial growth and pipeline execution. PTC Therapeutics Q2 Key Metrics Versus Estimates

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company’s research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.